Clinical Trial Update: A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib

View source ↗

Summary

A completed trial update reports real-world patient-reported outcomes for fedratinib in myelofibrosis patients who progressed or were intolerant to ruxolitinib.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• INREBIC (fedratinib hydrochloride)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Myelofibrosis | Status: COMPLETED